Our Tirzepatide represents the benchmark in high-purity metabolic research reagents, synthesized to mirror the precise mechanism of structural dual incretin mimetics. By acting as a robust agonist at both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) hormone receptors, this compound effectively regulates insulin secretion, delays gastric emptying, suppresses appetite, and optimizes cellular energy balance. It serves as a vital tool in investigating treatment pathways for obesity, metabolic syndrome, and type 2 diabetes.

To accommodate diverse laboratory and distribution frameworks, we offer this advanced peptide with fully customizable packaging layouts and box designs. Rather than limiting your supply to a single format, you can select from an array of specifications tailored directly to your brand or research requirements. Our available stock includes classic lyophilized powder configurations (spanning all standard weight increments from 2mg up to 120mg packaged securely at 10 vials per box), ready-to-ship card tubes without pens for rapid integration, oral tablets for alternative ingestion models, and raw bulk powder volumes for large-scale compounding.

Packaging Varieties:

• Lyophilized Powder Vials: 2mg, 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg, 80mg, 90mg, 100mg, 110mg, and 120mg specifications (10 vials per box).

• Cartridge Formats: Ready-to-ship card tubes without pens (available in 2.5mg, 5mg, 10mg, and 15mg specifications; 10 vials per box).

• Alternative Forms: Pre-formulated liquid injectables, custom oral tablets, or raw loose bulk powder material (available in 1g, 2g, and higher wholesale weights).